The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adjuvant modified FOLFIRINOX (mFFX) for resected pancreatic cancer (PDAC): Real world outcomes (RWO).
 
Fergus Keane
No Relationships to Disclose
 
Fiyinfolu Balogun
Honoraria - Mediflix (I)
Patents, Royalties, Other Intellectual Property - Mission Driven Tech. Brachytherapy (I)
 
Catherine O'Connor
No Relationships to Disclose
 
Fionnuala Crowley
No Relationships to Disclose
 
Amelia Chan
No Relationships to Disclose
 
Darren Cowzer
No Relationships to Disclose
 
Joanne F. Chou
No Relationships to Disclose
 
Wungki Park
Consulting or Advisory Role - Aegle; onconic therapeutics
Research Funding - Astellas Pharma (Inst); Gossamer Bio (Inst); Merck (Inst)
 
Anna M. Varghese
Consulting or Advisory Role - Lilly (I); Roche (I)
Research Funding - BioMed Valley Discoveries; Bristol-Myers Squibb; Illumina (I); Lilly; Silenseed; Verastem
Travel, Accommodations, Expenses - Roche (I)
 
Kenneth H. Yu
Consulting or Advisory Role - Ipsen
Research Funding - General Oncology (Inst); Ipsen; OncoC4 (Inst); Senhwa Biosciences (Inst)
 
James J. Harding
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; Elevar Therapeutics; Exelixis; Hepion Pharmaceuticals; Imvax; Lilly; Medivir; Merck; QED Therapeutics; Zymeworks
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Codiak Biosciences (Inst); Debiopharm Group (Inst); Genoscience Pharma (Inst); Genoscience Pharma (Inst); Incyte (Inst); Lilly (Inst); Loxo (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst); Yiviva (Inst); Zymeworks (Inst)
 
Marinela Capanu
No Relationships to Disclose
 
Jeffrey A. Drebin
Employment - American Regent (I)
Leadership - American Regent (I)
Stock and Other Ownership Interests - Alnylam; Arrowhead Pharmaceuticals; Ions Pharmaceuticals
 
T. Peter Kingham
Honoraria - Olympus Medical Systems
Consulting or Advisory Role - Physicans' Education Resource
 
Michael Ian D'Angelica
No Relationships to Disclose
 
Vinod P. Balachandran
Research Funding - Genentech/Roche (Inst)
Patents, Royalties, Other Intellectual Property - Inventors on a patent application related to work on antigen cross-reactivity and on a patent application related to work on neoantigen quality modeling.
 
William R. Jarnagin
No Relationships to Disclose
 
Alice Chia-chi Wei
Honoraria - AstraZeneca Canada; Medtronic
Consulting or Advisory Role - Biosapien; Histosonics
 
Kevin Soares
No Relationships to Disclose
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Adicet Bio (I); Alnylam (I); AstraZeneca; Autem Medical (I); BeiGene (I); Berry Genomics (I); BioSapien; BioSapien; Boehringer Ingelheim; Cend Therapeutics; CytomX Therapeutics; CytomX Therapeutics; Eisai (I); Exelixis (I); Flatiron Health (I); Genentech/Roche (I); Genoscience Pharma (I); Helio Health (I); IDEAYA Biosciences; Incyte (I); Ipsen; Legend Biotech (I); Merck; Nerviano Medical Sciences (I); Novartis; Noxxon Pharma; QED Therapeutics (I); Rafael Pharmaceuticals; RedHill Biopharma (I); Seagen; Thetis Pharma; Yiviva (I)
Research Funding - Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Celgene (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Parker Institute for Cancer Immunotherapy (Inst); Roche (Inst); Silenseed (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma